Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-11-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2013-07-511907PMID 24705490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker

  2014cited by this paper
• Prognostic value of arginase‐II expression and regulatory T‐cell infiltration in head and neck squamous cell carcinoma

  2013cited by this paper
• Arginase II Expressed in Cancer-Associated Fibroblasts Indicates Tissue Hypoxia and Predicts Poor Outcome in Patients with Pancreatic Cancer

  2013cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012cited by this paper
• Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

  2012cited by this paper
• Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

  2012cited by this paper
• Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

  2012cited by this paper
• Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.

  2012cited by this paper
• Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

  2012cited by this paper
• CHI3L1 (YKL‐40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells

  2011cited by this paper
• Metabolic regulation of hematopoietic stem cells in the hypoxic niche.

  2011cited by this paper
• Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

  2011cited by this paper
• Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

  2011cited by this paper
• Leukemia stem cells and microenvironment: biology and therapeutic targeting.

  2011cited by this paper
• Chronic myeloid leukemia

  2011cited by this paper
• HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells.

  2011cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011cited by this paper
• Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

  2010cited by this paper
• Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

  2010cited by this paper
• Regulation of the HIF-1alpha level is essential for hematopoietic stem cells.

  2010cited by this paper
• Epigenetics: The epicenter of the hypoxic response

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment

  2010cited by this paper
• Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

  2010cited by this paper
• Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.

  2010cited by this paper
• Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming

  2010cited by this paper
• Oxygen in stem cell biology: a critical component of the stem cell niche.

  2010cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• The Allen Brain Atlas: 5 years and beyond

  2009cited by this paper
• Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells

  2009cited by this paper
• The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells

  2009cited by this paper
• HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells

  2009cited by this paper
• Generating specificity and diversity in the transcriptional response to hypoxia

  2009cited by this paper
• CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.

  2009cited by this paper
• Role of hypoxia-inducible factor in cell survival during myocardial ischemia–reperfusion

  2008cited by this paper
• The role of oxygen availability in embryonic development and stem cell function

  2008cited by this paper
• Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

  2008cited by this paper
• The impact of O2 availability on human cancer

  2008cited by this paper
• Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

  2008cited by this paper
• Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells

  2007cited by this paper
• Oncogenic properties of a novel gene JK-1 located in chromosome 5p and its overexpression in human esophageal squamous cell carcinoma.

  2007cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

  2007cited by this paper
• Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia

  2007cited by this paper
• Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

  2007cited by this paper
• Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

  2007cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor1

  2006cited by this paper
• A novel normalization method for effective removal of systematic variation in microarray data

  2006cited by this paper
• Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

  2006cited by this paper
• PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

  2006cited by this paper
• Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations

  2006cited by this paper
• Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.

  2006cited by this paper
• The stem cell niches in bone.

  2006cited by this paper
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

  2005cited by this paper
• Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

  2005influential reference
• Discontinuation of imatinib therapy after achieving a molecular response.

  2004cited by this paper
• BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

  2004cited by this paper
• Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression.

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Expansion of human SCID-repopulating cells under hypoxic conditions.

  2003cited by this paper
• BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

  2002influential reference
• Oxygen saturation in the bone marrow of healthy volunteers.

  2002cited by this paper
• Hypoxia Modifies Proliferation and Differentiation of CD34+ CML Cells

  2002cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM.

  1997cited by this paper

• Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells

  2026cites this paper
• Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells

  2026cites this paper
• Exploring phytochemical inhibitors of fatty acid elongase ELOVL6 for targeted treatment of chronic myeloid leukemia: A comprehensive network-based drug discovery approach

  2025cites this paper
• The Role of the Bone Marrow Microenvironment in Leukemic Stem Cell Resistance: Pathways of Persistence and Selection.

  2025cites this paper
• CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors

  2025cites this paper
• Chronic myeloid leukaemia: Biology and therapy.

  2024cites this paper
• Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview

  2024cites this paper
• Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients

  2024cites this paper
• HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR

  2024cites this paper
• mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells

  2023influential citation
• The emerging role of microRNA-22 in the Leukemia: experimental and clinical implications

  2023cites this paper
• Cancer Stem Cells in Carcinogenesis and Potential Role in Pancreatic Cancer.

  2023cites this paper
• Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

  2023cites this paper
• Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells.

  2023cites this paper
• Clonal selection parallels between normal and cancer tissues.

  2023cites this paper
• Metabolism in stem cell–driven leukemia: parallels between hematopoiesis and immunity

  2023cites this paper
• TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment

  2023cites this paper
• Role and regulation of autophagy in cancer.

  2022cites this paper
• ER stress as a trigger of UPR and ER-phagy in cancer growth and spread

  2022cites this paper
• Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

  2022cites this paper
• Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells

  2022cites this paper
• Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells

  2022cites this paper
• Hypoxic stress and hypoxia-inducible factors in leukemias

  2022cites this paper
• Action Sites and Clinical Application of HIF-1α Inhibitors

  2022cites this paper
• Cancer Stem Cells: The Greatest Menace in Conquering Cancer Management

  2022cites this paper
• Mechanisms of cancer stem cells drug resistance and the pivotal role of HMGA2.

  2022cites this paper
• Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress

  2022cites this paper
• The suppressive functions of Rora in B lineage cell proliferation and BCR/ABL1-induced B-ALL pathogenesis

  2022cites this paper
• Cancer cells adapt FAM134B-BiP complex mediated ER-phagy to survive hypoxic stress

  2021cites this paper
• Chronic myeloid leukemia stem cells: targeting therapeutic implications

  2021influential citation
• Tumor Microenvironment

  2021cites this paper
• Effect of hypoxia on proliferation and glucocorticoid resistance of T-cell acute lymphoblastic leukaemia

  2021cites this paper
• Breakthrough Science: Hypoxia-Inducible Factors, Oxygen Sensing, and Disorders of Hematopoiesis.

  2021cites this paper
• Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

  2021cites this paper
• miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool

  2021cites this paper
• The regulation of bcr-abl in hypoxia is through the mTOR pathway

  2020cites this paper
• Imatinib Revives the Therapeutic Potential of Metformin on Ewing Sarcoma by Attenuating Tumor Hypoxic Response and Inhibiting Convergent Signaling Pathways.

  2020cites this paper
• Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance

  2020cites this paper
• Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease

  2020cites this paper
• SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia

  2020cites this paper
• The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression.

  2020cites this paper
• A nano-based thermotherapy for cancer stem cell-targeted therapy.

  2020cites this paper
• Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells

  2020cites this paper
• Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.

  2020cites this paper
• Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment

  2020cites this paper
• DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells

  2020cites this paper
• Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia

  2019cites this paper
• Chronic myeloid leukemia stem cells

  2019cites this paper
• Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.

  2019cites this paper
• Chronic myelogenous leukemia Chronic myeloid leukemia stem cells

  2019cites this paper
• Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role

  2019cites this paper
• PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions

  2018cites this paper
• Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429

  2018cites this paper
• : Chronic Myeloid Leukemia : Stem Cell Niche and Response to Pharmacologic Treatment

  2018cites this paper
• Hypoxia Signaling Pathway in Stem Cell Regulation: Good and Evil

  2018cites this paper
• The role of hypoxia-inducible factors in leukemias.

  2018cites this paper
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

  2018cites this paper
• Hypoxia and Selective Autophagy in Cancer Development and Therapy

  2018cites this paper
• The arginase inhibitor Nω−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target

  2018cites this paper
• SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis

  2018cites this paper
• Imatinib: Basic Results

  2017cites this paper
• Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

  2017influential citation
• Associated Risk of Malignancy in Patients with Cardiovascular Disease: Evidence and Possible Mechanism.

  2017cites this paper
• Mitochondria and stem cell function: from somatic cells to iPSC-based disease modeling

  2017cites this paper
• Integration of hypoxic HIF-α signaling in blood cancers

  2017cites this paper
• Myeloid malignancies and the microenvironment.

  2017cites this paper
• Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia

  2017cites this paper
• Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

  2017cites this paper
• Hypoxia-inducible factor 1 alpha (HIF-1α) and its prognostic value in acute myeloid leukemia

  2017cites this paper
• The chronic myeloid leukemia stem cell: stemming the tide of persistence.

  2017cites this paper
• Codelivery of Ponatinib and SAR302503 by Active Bone-Targeted Polymeric Micelles for the Treatment of Therapy-Resistant Chronic Myeloid Leukemia.

  2017cites this paper
• Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells

  2017cites this paper
• Prognostic markers associated with tyrosine kinase inhibitor treatment response and maintenance of treatment free remission in chronic myeloid leukaemia

  2016cites this paper
• Cancer Stem Cells: Basic Concepts and Therapeutic Implications.

  2016cites this paper
• The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.

  2016cites this paper
• Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin

  2016cites this paper
• Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury.

  2016cites this paper
• Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions

  2016cites this paper
• Cancer Stem Cells : Basic Concepts and Therapeutic Implications

  2016cites this paper
• New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.

  2016cites this paper
• Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.

  2016cites this paper
• Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia

  2016cites this paper
• Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy

  2016cites this paper
• Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis

  2016cites this paper
• Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• The importance of hypoxia and extra physiologic oxygen shock/stress for collection and processing of stem and progenitor cells to understand true physiology/pathology of these cells ex vivo

  2015cites this paper
• Cancer and cancer stem cell targeting agents : A focus on salinomycin and apoptin

  2015cites this paper
• Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

  2015influential citation
• Hypoxia-inducible factors in cancer stem cells and inflammation.

  2015cites this paper
• Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors

  2015cites this paper
• WNT16-expressing Acute Lymphoblastic Leukemia Cells are Sensitive to Autophagy Inhibitors after ER Stress Induction.

  2015cites this paper
• A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression

  2015cites this paper
• Cellular and Molecular Mechanisms Underlying Oxygen-Dependent Radiosensitivity

  2015influential citation
• A hostel for the hostile: the bone marrow niche in hematologic neoplasms

  2015cites this paper
• Hypoxia regulates the hematopoietic stem cell niche

  2015influential citation
• An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool

  2014cites this paper
• Molecular biology and cytogenetics of chronic myeloid leukemia

  2013cites this paper